Alnylam Pharmaceuticals, Inc. (ALNY): Price and Financial Metrics

Alnylam Pharmaceuticals, Inc. (ALNY): $187.40

0.45 (+0.24%)

POWR Rating

Component Grades













Add ALNY to Watchlist
Sign Up

Industry: Biotech


of 505

in industry


  • Growth is the dimension where ALNY ranks best; there it ranks ahead of 79.62% of US stocks.
  • The strongest trend for ALNY is in Value, which has been heading up over the past 48 weeks.
  • ALNY's current lowest rank is in the Momentum metric (where it is better than 5.12% of US stocks).

ALNY Stock Summary

  • ALNY's price/sales ratio is 32.32; that's higher than the P/S ratio of 92.99% of US stocks.
  • With a year-over-year growth in debt of 141.56%, Alnylam Pharmaceuticals Inc's debt growth rate surpasses 93.54% of about US stocks.
  • As for revenue growth, note that ALNY's revenue has grown 99.18% over the past 12 months; that beats the revenue growth of 93.42% of US companies in our set.
  • Stocks that are quantitatively similar to ALNY, based on their financial statements, market capitalization, and price volatility, are SDGR, GNTX, MTSI, CDXS, and ENTX.
  • Visit ALNY's SEC page to see the company's official filings. To visit the company's web site, go to

ALNY Valuation Summary

  • ALNY's price/earnings ratio is -27; this is 173.97% lower than that of the median Healthcare stock.
  • ALNY's EV/EBIT ratio has moved down 28.4 over the prior 210 months.
  • Over the past 210 months, ALNY's price/sales ratio has gone down 400.7.

Below are key valuation metrics over time for ALNY.

Stock Date P/S P/B P/E EV/EBIT
ALNY 2021-08-31 34.8 28.1 -27.0 -31.5
ALNY 2021-08-30 35.2 28.3 -27.3 -31.8
ALNY 2021-08-27 35.3 28.4 -27.3 -31.9
ALNY 2021-08-26 35.0 28.2 -27.1 -31.6
ALNY 2021-08-25 35.4 28.5 -27.5 -32.0
ALNY 2021-08-24 34.9 28.1 -27.1 -31.6

ALNY Growth Metrics

  • Its year over year price growth rate is now at -3.84%.
  • Its 2 year revenue growth rate is now at 207.95%.
  • Its 3 year price growth rate is now at 43.67%.
Over the past 33 months, ALNY's revenue has gone up $595,735,000.

The table below shows ALNY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 687.534 -590.986 -886.681
2021-03-31 570.943 -604.46 -876.351
2020-12-31 492.853 -614.961 -858.281
2020-09-30 400.972 -687.797 -890.926
2020-06-30 345.18 -760.103 -846.17
2020-03-31 285.932 -336.078 -886.422

ALNY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALNY has a Quality Grade of C, ranking ahead of 41.92% of graded US stocks.
  • ALNY's asset turnover comes in at 0.204 -- ranking 199th of 677 Pharmaceutical Products stocks.
  • CASI, TXMD, and QGEN are the stocks whose asset turnover ratios are most correlated with ALNY.

The table below shows ALNY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.204 0.833 -0.267
2021-03-31 0.171 0.832 -0.272
2020-12-31 0.159 0.842 -0.308
2020-09-30 0.141 0.832 -0.372
2020-06-30 0.130 0.853 -0.416
2020-03-31 0.115 0.878 -0.526

ALNY Price Target

For more insight on analysts targets of ALNY, see our ALNY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $184.16 Average Broker Recommendation 1.67 (Moderate Buy)

ALNY Stock Price Chart Interactive Chart >

Price chart for ALNY

ALNY Price/Volume Stats

Current price $187.40 52-week high $209.73
Prev. close $186.95 52-week low $119.29
Day low $185.40 Volume 228,200
Day high $189.08 Avg. volume 635,507
50-day MA $190.71 Dividend yield N/A
200-day MA $159.11 Market Cap 22.27B

Alnylam Pharmaceuticals, Inc. (ALNY) Company Bio

Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company was founded in 2002 and is based in Cambridge, Massachusetts.

ALNY Latest News Stream

Event/Time News Detail
Loading, please wait...

ALNY Latest Social Stream

Loading social stream, please wait...

View Full ALNY Social Stream

Latest ALNY News From Around the Web

Below are the latest news stories about Alnylam Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran

Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

Yahoo | September 14, 2021

Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with polyneuropathy. “hATTR amyloidosis is a rare, rapidly progressive, debilitating and fatal condition and we are d

Business Wire | September 13, 2021

Alnylam Pharma Submits MAA To EMA For Vutrisiran For Hereditary ATTR Amyloidosis With Polyneuropathy

(RTTNews) - RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Monday the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with

Business Insider Markets | September 13, 2021

PNH and aHUS Market Competitive Research And Precise Outlook 2021 To 2027- Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Omeros Corporation

PNH and aHUS Market Research Report 2021 - 2027 Latest released, the research study on Global PNH and aHUS Market Report Forecast 2021 - 2027, offers a detailed overview of the factors influencing the global business scope. PNH and aHUS Market

OpenPR | September 9, 2021

Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting

CAMBRIDGE, Mass., September 07, 2021--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced additional positive results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis. Data presented at the 3rd European ATTR Amyloidosis Meeting further supports and builds on the previously reported primary a

Yahoo | September 7, 2021

Read More 'ALNY' Stories Here

ALNY Price Returns

1-mo -8.55%
3-mo 6.85%
6-mo 37.54%
1-year 40.54%
3-year 99.60%
5-year 147.98%
YTD 44.19%
2020 12.85%
2019 57.96%
2018 -42.61%
2017 239.34%
2016 -60.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8493 seconds.